Marker Therapeutics (NASDAQ:MRKR) Trading Down 1.9% – Should You Sell?

Marker Therapeutics, Inc. (NASDAQ:MRKR) was down 1.9% during mid-day trading on Monday . The company traded as low as $1.56 and last traded at $1.57. Approximately 76,501 shares were traded during trading, a decline of 5% from the average daily volume of 80,166 shares. The stock had previously closed at $1.60.

Analyst Upgrades and Downgrades

Separately, WBB Securities reaffirmed a “strong-buy” rating and set a $12.50 price objective on shares of Marker Therapeutics in a research report on Tuesday, April 1st.

Marker Therapeutics Stock Performance

The stock has a market cap of $17.76 million, a PE ratio of -1.18 and a beta of 1.43. The stock’s 50-day moving average is $1.37 and its two-hundred day moving average is $1.66.

Hedge Funds Weigh In On Marker Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new position in Marker Therapeutics in the 4th quarter valued at approximately $50,000. Northern Trust Corp boosted its position in Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after buying an additional 21,703 shares during the period. LPL Financial LLC purchased a new position in Marker Therapeutics in the 4th quarter valued at approximately $248,000. Aisling Capital Management LP boosted its position in Marker Therapeutics by 3.5% in the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after buying an additional 11,084 shares during the period. Finally, Blue Owl Capital Holdings LP purchased a new position in Marker Therapeutics in the 4th quarter valued at approximately $1,724,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.